Vestal Point Capital, LP — 13F Holdings & Portfolio

CIK 1974915 · latest 13F-HR filed 2026-08-14

Vestal Point Capital, LP manages $4.28B in 13F-reported U.S. long-equity assets across 68 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BMRN (8.06%), NBIX (7.40%), ABVX (7.32%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 33; 36 existing positions rose in reported value and 18 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$4.28B

Long-equity book

Holdings
68

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+11 / −33 / ↑36 / ↓18

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 50.3%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$5.47B
Discretionary
$5.47B
Employees
11
Accounts
4
Address
632 BROADWAY
SUITE 602
NEW YORK, NY 10012
Phone
(646) 989-4000
Name Title / Status Ownership Type
CARROLL, BENJAMIN, GERMAN ControlCHIEF FINANCIAL OFFICER
since Mar 2025
Less than 5%Individual
MENKOV, ILKO, LATCHEZAROV ControlPARTNER, COO AND CCO
since Apr 2023
5–10%Individual
VESTAL POINT CAPITAL, LLC ControlGENERAL PARTNER
since Apr 2023
Less than 5%Domestic Entity
WILDER, RYAN, CHRISTOPHER ControlMANAGING PARTNER AND CHIEF INVESTMENT OFFICER
since Apr 2023
25–50%Individual
MAPLEWOOD 1 HOLDINGS LLCLIMITED PARTNER
since Jan 2026
25–50%Domestic Entity
WILDER, RYAN, CHRISTOPHER Control
Indirect owner via VESTAL POINT CAPITAL, LLC
MANAGER
since Apr 2023
25–50%Individual
J.P. MORGAN TRUST COMPANY OF DELAWARE
Indirect owner via MAPLEWOOD 1 TRUST
ADMINISTRATIVE TRUSTEE
since Dec 2025
25–50%Domestic Entity
MAPLEWOOD 1 TRUST
Indirect owner via MAPLEWOOD 1 HOLDINGS LLC
SOLE OWNER
since Dec 2025
25–50%Domestic Entity
WILDER, BLYTHE, ADLER
Indirect owner via MAPLEWOOD 1 HOLDINGS LLC
MANAGER
since Dec 2025
25–50%Individual
Ownership & leadership changes · 2 filings with changes since Mar 17, 2023

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2026 filing
  • AddedJ.P. MORGAN TRUST COMPANY OF DELAWARE · ADMINISTRATIVE TRUSTEE · 25–50% · indirect via MAPLEWOOD 1 TRUST
  • AddedMAPLEWOOD 1 HOLDINGS LLC · LIMITED PARTNER · 25–50%
  • AddedMAPLEWOOD 1 TRUST · SOLE OWNER · 25–50% · indirect via MAPLEWOOD 1 HOLDINGS LLC
  • AddedVESTAL POINT CAPITAL, LLC · GENERAL PARTNER · Less than 5% · control person
  • AddedWILDER, BLYTHE, ADLER · MANAGER · 25–50% · indirect via MAPLEWOOD 1 HOLDINGS LLC
  • AddedWILDER, RYAN, CHRISTOPHER · MANAGER · 25–50% · indirect via VESTAL POINT CAPITAL, LLC · control person
  • ChangedWILDER, RYAN, CHRISTOPHER · ownership 75% or more → 25–50%
Mar 21, 2025 filing
  • AddedCARROLL, BENJAMIN, GERMAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Mar 17, 2023 filing (earliest on record)
  • ListedMENKOV, ILKO, LATCHEZAROV · PARTNER, COO AND CCO · 5–10% · control person
  • ListedWILDER, RYAN, CHRISTOPHER · MANAGING PARTNER AND CHIEF INVESTMENT OFFICER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Vestal Point Capital, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 BioMarin Pharmaceutical Inc BMRN 09061G101 $344.8M 8.06% 6,025,000 SH
2 Neurocrine Biosciences Inc NBIX 64125C109 $316.8M 7.40% 1,880,000 SH
3 Abivax SA ABVX 00370M103 $313.1M 7.32% 2,349,443 SH
4 United Therapeutics Corp UTHR 91307C102 $235.7M 5.51% 435,000 SH
5 Enliven Therapeutics Inc ELVN 29337E102 $203.0M 4.74% 4,000,000 SH
6 Nurix Therapeutics Inc NRIX 67080M103 $195.3M 4.56% 8,050,000 SH
7 Bicara Therapeutics Inc BCAX 055477103 $155.9M 3.64% 5,250,000 SH
8 Taysha Gene Therapies Inc TSHA 877619106 $132.2M 3.09% 19,415,000 SH
9 Arrowhead Pharmaceuticals Inc ARWR 04280A100 $128.4M 3.00% 1,575,000 SH
10 Abbott Laboratories ABT 002824100 $127.0M 2.97% 1,400,000 SH
11 Zimmer Biomet Holdings Inc ZBH 98956P102 $120.5M 2.82% 1,400,000 SH
12 Disc Medicine Inc IRON 254604101 $113.4M 2.65% 1,550,000 SH
13 Monte Rosa Therapeutics Inc GLUE 61225M102 $111.3M 2.60% 4,600,000 SH
14 Insulet Corp PODD 45784P101 $102.0M 2.38% 670,000 SH
15 Ascendis Pharma A/S ASND K08588103 $100.0M 2.34% 375,000 SH
16 AstraZeneca PLC AZN G0593M107 $85.3M 1.99% 450,000 SH
17 Sanofi SA SNY 80105N105 $85.3M 1.99% 2,000,000 SH
18 Revolution Medicines Inc RVMD 76155X100 $84.3M 1.97% 450,000 SH
19 BioCryst Pharmaceuticals Inc BCRX 09058V103 $83.0M 1.94% 8,300,000 SH
20 Dyne Therapeutics Inc DYN 26818M108 $75.0M 1.75% 3,375,000 SH
21 Nektar Therapeutics NKTR 640268306 $69.8M 1.63% 1,000,000 SH
22 Globus Medical Inc GMED 379577208 $67.2M 1.57% 850,000 SH
23 Tarsus Pharmaceuticals Inc TARS 87650L103 $66.1M 1.54% 1,050,000 SH
24 Immatics NV IMTX N44445109 $62.6M 1.46% 6,175,000 SH
25 Trevi Therapeutics Inc TRVI 89532M101 $57.8M 1.35% 3,100,000 SH
26 Immunocore Holdings PLC IMCR 45258D105 $57.1M 1.34% 1,800,000 SH
27 Repligen Corp RGEN 759916109 $54.6M 1.28% 400,000 SH
28 Bristol-Myers Squibb Co BMY 110122108 $46.1M 1.08% 800,000 SH
29 uniQure NV QURE N90064101 $43.1M 1.01% 935,000 SH
30 Xenon Pharmaceuticals Inc XENE 98420N105 $42.3M 0.99% 700,000 SH
31 Bright Minds Biosciences Inc DRUG 10919W405 $38.3M 0.89% 545,000 SH
32 Madrigal Pharmaceuticals Inc MDGL 558868105 $34.9M 0.82% 65,000 SH
33 Alcon AG ALC H01301128 $33.5M 0.78% 500,000 SH
34 Myriad Genetics Inc MYGN 62855J104 $32.7M 0.77% 5,735,000 SH
35 Rapport Therapeutics Inc RAPP 75383L102 $30.4M 0.71% 730,000 SH
36 Crescent Biopharma Inc CBIO G2545C104 $29.3M 0.69% 1,630,000 SH
37 GE HealthCare Technologies Inc GEHC 36266G107 $28.8M 0.67% 450,000 SH
38 Insmed Inc INSM 457669307 $26.7M 0.62% 250,000 SH
39 Viking Therapeutics Inc VKTX 92686J106 $26.5M 0.62% 680,000 SH
40 Beta Bionics Inc BBNX 08659B102 $25.1M 0.59% 1,600,000 SH
41 Regeneron Pharmaceuticals Inc REGN 75886F107 $24.9M 0.58% 40,000 SH
42 Solid Biosciences Inc SLDB 83422E204 $21.6M 0.50% 2,160,000 SH
43 Alto Neuroscience Inc ANRO 02157Q109 $20.7M 0.48% 785,000 SH
44 First Tracks Biotherapeutics I TRAX 337185102 $20.4M 0.48% 1,013,000 SH
45 Lexeo Therapeutics Inc LXEO 52886X107 $20.1M 0.47% 4,320,000 SH
46 Savara Inc SVRA 805111101 $16.8M 0.39% 2,720,000 SH
47 Damora Therapeutics Inc DMRA 36322Q206 $15.0M 0.35% 575,000 SH
48 SpyGlass Pharma Inc SGP 85220G109 $14.9M 0.35% 670,000 SH
49 Tectonic Therapeutic Inc TECX 878972108 $14.6M 0.34% 425,000 SH
50 Avalo Therapeutics Inc AVTX 05338F306 $14.3M 0.33% 775,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $4.28B 68 0001974915-26-000005
2026-03-31 2026-05-15 $3.58B 90 0001974915-26-000004
2025-12-31 2026-02-17 $2.94B 76 0001974915-26-000002
2025-09-30 2025-11-14 $2.21B 81 0001974915-25-000008
Filer Information
Address
632 BROADWAY
SUITE 602
NEW YORK, NY 10012
Phone
(646) 989-4000
Filing Manager
Vestal Point Capital, LP
NEW YORK, NY
Signatory
Ilko Menkov
Partner, COO and CCO